Varenicline: An α4 Β2 nicotinic acetylcholine receptor partial agonist as an aid to smoking cessation

Medication Treatments for Nicotine Dependence

Volumn , Issue , 2006, Pages 213-221

  Oncken, Cheryl A ^a   Gonzales, David ^b   Nides, Mitchell ^c   Rennard, Steven ^d   Watsky, Eric J ^e   Coe, Jotham W ^e  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Los Angeles Clinical Trials   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68549089216     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (26)

1. APA, Diagnostic and Statistical Manual of Mental Disorders (DSM-IVR), 4th ed. (rev.), American Psychiatric Association, Washington, D.C., 2000.
2. Henningfield, J.E., Nicotine medications for smoking cessation, New Engl. J. Med., 333(18), 1196-1203, 1995.
3. Dani, J.A. and De Biasi, M., Cellular mechanisms of nicotine addiction, Pharmacol. Biochem. Behav., 70(4), 439-446, 2001.
4. Di Chiara, G., Role of dopamine in the behavioural actions of nicotine related addiction, Eur. J. Pharmacol., 393, 295-314, 2000.
5. Di Chiara, G. and Imperato, A., Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats, Proc. Natl. Acad. Sci. USA, 85(14), 5274-5278, 1988.
6. Pontieri, F.E. et al., Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs [see comment], Nature, 382(6588), 255-257, 1996.
7. Tapper, A.R. et al., Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization, Science, 306(5698), 1029-1032, 2004.
8. Picciotto, M.R. et al., Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine, Nature, 391(6663), 173-177, 1998.
9. Maskos, U. et al., Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors, Nature, 436(7047), 103-107, 2005.
10. Scharfenberg, G., Benndorf, S., and Kempe, G., Cytisine (Tabex) as a pharmaceutical aid in stopping smoking [in German], Dtsch. Gesundheitsw., 26(10), 463-465, 1971.
11. Papke, R.L. and Heinemann, S.F., Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit, Mol. Pharmacol., 45(1), 142-149, 1994.
12. Barlow, R.B. and McLeod, L.J., Some studies on cytisine and its methylated derivatives, Br. J. Pharmacol., 35(1), 161-174, 1969.
13. Reavill, C. et al., Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline, Neuropharmacology, 29(7), 619-624, 1990.
14. Rose, J.E. et al., Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone, Clin. Pharmacol. Ther., 56, 86-99, 1994.
15. Jasinski, D.R., Pevnick, J.S., and Griffith, J.D., Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction, Arch. Gen. Psychiatry, 35(4), 501-516, 1978.
16. Vocci, F.J., Acri, J., and Elkashef, A., Medication development for addictive disorders: the state of the science, Am. J. Psychiatry, 162(8), 1432-1440, 2005.
17. Coe, J.W. et al., In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine, Bioorg. Med. Chem. Lett., 15(12), 2974-9, 2005.
18. Coe, J.W. et al.,3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation, Bioorg. Med. Chem. Lett., 15(22), 4889-4897, 2005.
19. Coe, J.W. et al., Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation, J. Med. Chem., 48(10), 3474-3477, 2005.
20. Mansbach, R.S., Chambers, L.K., and Rovetti, C.C., Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine, Psychopharmacology, 148(3), 234-242, 2000.
21. 2 acetylcholine receptor partial agonist, in vivo and in vitro, Drug Metab. Dispos., 34(1), 121-130, 2006.
22. Faessel, H. et al., Safety, tolerability, and pharmacokinetic evaluation of concomitant administration of varenicline and digoxin or warfarin, in Proc. of the 11th Annual Meeting and 7th Annual European Conf. of the Society for Research on Nicotine and Tobacco, Prague, 2005.
23. Burstein, A. et al., Safety, tolerability, and multi-dose pharmacokinetics of varenicline in elderly smokers, in Proc. of the 11th Annual Meeting and 7th Annual European Conf. of the Society for Research on Nicotine and Tobacco, Prague, 2005.
24. 2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with one-year follow-up, Arch. Intern. Med., in press.
25. Oncken, C. et al., Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a phase 2 study, in Proc. of the 11th Annual Meeting and 7th Annual European Conf. of the Society for Research on Nicotine and Tobacco, Prague, 2005.
26. 2 nicotinic receptor partial agonist-results from varenicline in cessation therapy: optimizing results, in Proc. of the American Heart Association Annual Meeting, Dallas, TX, 2005.